Nicholas C. Turner

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

Medicine, Oncology, Pharmacology +17

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +10

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Alessandra Gennari, Fabrice André, Carlos H. Barrios et al. · Annals of Oncology · 2021 · 1.4K citations · Full text

Medicine, Oncology, Surgery +14

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

Nuala McCabe, Nicholas C. Turner, Christopher J. Lord et al. · Cancer Research · 2006 · 1.3K citations

Life Sciences, Molecular Biology, Oncology +17

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17